<DOC>
	<DOCNO>NCT02498990</DOCNO>
	<brief_summary>The primary hypothesis investigate whether low calorie diet 7 week follow continuous lifestyle advice effective option achieve improvement glucose control measure HbA1c 52 104 week compare baseline value obese type 2 diabetes patient either tablet insulin treatment . The secondary hypothesis investigate whether weight reduction therapy also significant impact various anthropometric , clinical metabolic parameter associate obesity .</brief_summary>
	<brief_title>Low Calorie Diet Diabetes</brief_title>
	<detailed_description>This prospective study impact low calorie diet follow weight maintenance program 12 24 month glucose control cohort patient obesity diabetes mellitus . The study consist 3 phase : 1 . Screening period ( 12 week ) . 2 . Low calorie diet week 1-9 . Seven week low-calorie diet include 800 kcal/day follow 2 week gradual introduction normal diet eventually 1500-2000 kcal/day , i.e . 600 kcal/day deficit , base present body weight sex . At entry LCD-period , medication diabetes mellitus , exception metformin insulin , remove . During LCD-period , insulin treatment gradually reduce , possible , withdrawn . Patients perform daily self-monitoring fast post-prandial plasma glucose . At visit , take place week , patient see physician , nurse dietician . The patient give specific advice increase physical activity . Patients remain medication dyslipidemia . Blood pressure measure visit case blood pressure &lt; 110/70 mmHg and/or case symptom associate hypotension include dizziness , medication hypertension reduce remove . 3 . Weight-maintenance program week 10-52 . 4 . Follow visit month 15 , 18 , 21 24 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Men woman age 1865 year screen . 2 . Diagnosis type 2 diabetes mellitus . 3 . BMI &gt; 30 kg/m2 . 4 . HbA1c &gt; 52 mmol/mol . 5 . Stable weight ± 5 % least 12 week prior screen . 6 . Informed consent must obtain subject enrollment study . 1 . Pregnant brestfeeding woman woman plan become pregnant breastfeeding . 2 . Type 1 diabetes mellitus secondary form diabetes include pancreatic injury , cushing syndrome etc . 3 . Clinically significant diabetic complication 4 . Clinically symptomatic gastrointestinal hepatic disease . 5 . History gastric bypass , antrectomy small bowel disease . 6 . History pancreatitis . 7 . Myocardial infarction within past six month . 8 . Symptomatic ischemic heart disease , heart failure stroke . 9 . Atrial fibrillation . 10 . Patients treatment warfarin . 11 . Diagnosed and/or treated malignancy within past 5 year . 12 . Any following laboratory abnormality screen : ALT and/or AST &gt; 3 time upper limit normal range . Serum creatinine level &gt; 130 µmol/l . Clinically significant TSH normal range . Uric acid &gt; 50 % normal level . 13 . History alcohol substance abuse within past 2 year . 14 . Psychiatric disease include eat disorder , bulimia nervosa , depression , anxiety , psychotic disease . 15 . Potentially unreliable patient judge investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>